Your browser doesn't support javascript.
loading
Virus-like particles displaying the mature C-terminal domain of filamentous hemagglutinin are immunogenic and protective against Bordetella pertussis respiratory infection in mice.
Pyles, Gage M; Huckaby, Annalisa B; Gutierrez, Maria de la Paz; Witt, William T; Mateu-Borrás, Margalida; Dublin, Spencer R; Rocuskie-Marker, Carleena; Sesti, Bethany N; Peasak, Kerrington; Bitzer, Graham J; Rader, Nathaniel; Weaver, Kelly L; Boehm, Dylan T; Fitzgerald, Nicholas; Chapman, Joshua; Ulicny, Samuel; Damron, F Heath; Barbier, Mariette.
Afiliación
  • Pyles GM; Department of Microbiology, Immunology and Cell Biology, West Virginia University , Morgantown, West Virginia, USA.
  • Huckaby AB; Vaccine Development Center, West Virginia University Health Sciences Center , Morgantown, West Virginia, USA.
  • Gutierrez MdlP; Department of Microbiology, Immunology and Cell Biology, West Virginia University , Morgantown, West Virginia, USA.
  • Witt WT; Vaccine Development Center, West Virginia University Health Sciences Center , Morgantown, West Virginia, USA.
  • Mateu-Borrás M; Department of Microbiology, Immunology and Cell Biology, West Virginia University , Morgantown, West Virginia, USA.
  • Dublin SR; Vaccine Development Center, West Virginia University Health Sciences Center , Morgantown, West Virginia, USA.
  • Rocuskie-Marker C; Department of Microbiology, Immunology and Cell Biology, West Virginia University , Morgantown, West Virginia, USA.
  • Sesti BN; Vaccine Development Center, West Virginia University Health Sciences Center , Morgantown, West Virginia, USA.
  • Peasak K; Department of Microbiology, Immunology and Cell Biology, West Virginia University , Morgantown, West Virginia, USA.
  • Bitzer GJ; Vaccine Development Center, West Virginia University Health Sciences Center , Morgantown, West Virginia, USA.
  • Rader N; Department of Microbiology, Immunology and Cell Biology, West Virginia University , Morgantown, West Virginia, USA.
  • Weaver KL; Vaccine Development Center, West Virginia University Health Sciences Center , Morgantown, West Virginia, USA.
  • Boehm DT; Department of Microbiology, Immunology and Cell Biology, West Virginia University , Morgantown, West Virginia, USA.
  • Fitzgerald N; Vaccine Development Center, West Virginia University Health Sciences Center , Morgantown, West Virginia, USA.
  • Chapman J; Department of Microbiology, Immunology and Cell Biology, West Virginia University , Morgantown, West Virginia, USA.
  • Ulicny S; Vaccine Development Center, West Virginia University Health Sciences Center , Morgantown, West Virginia, USA.
  • Damron FH; Department of Microbiology, Immunology and Cell Biology, West Virginia University , Morgantown, West Virginia, USA.
  • Barbier M; Vaccine Development Center, West Virginia University Health Sciences Center , Morgantown, West Virginia, USA.
Infect Immun ; 92(8): e0027024, 2024 Aug 13.
Article en En | MEDLINE | ID: mdl-39023271
ABSTRACT
Bordetella pertussis, the bacterium responsible for whooping cough, remains a significant public health challenge despite the existing licensed pertussis vaccines. Current acellular pertussis vaccines, though having favorable reactogenicity and efficacy profiles, involve complex and costly production processes. In addition, acellular vaccines have functional challenges such as short-lasting duration of immunity and limited antigen coverage. Filamentous hemagglutinin (FHA) is an adhesin of B. pertussis that is included in all multivalent pertussis vaccine formulations. Antibodies to FHA have been shown to prevent bacterial attachment to respiratory epithelial cells, and T cell responses to FHA facilitate cell-mediated immunity. In this study, FHA's mature C-terminal domain (MCD) was evaluated as a novel vaccine antigen. MCD was conjugated to virus-like particles via SpyTag-SpyCatcher technology. Prime-boost vaccine studies were performed in mice to characterize immunogenicity and protection against the intranasal B. pertussis challenge. MCD-SpyVLP was more immunogenic than SpyTag-MCD antigen alone, and in Tohama I strain challenge studies, improved protection against challenge was observed in the lungs at day 3 and in the trachea and nasal wash at day 7 post-challenge. Furthermore, a B. pertussis strain encoding genetically inactivated pertussis toxin was used to evaluate MCD-SpyVLP vaccine immunity. Mice vaccinated with MCD-SpyVLP had significantly lower respiratory bacterial burden at both days 3 and 7 post-challenge compared to mock-vaccinated animals. Overall, these data support the use of SpyTag-SpyCatcher VLPs as a platform for use in vaccine development against B. pertussis and other pathogens.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bordetella pertussis / Vacuna contra la Tos Ferina / Tos Ferina / Adhesinas Bacterianas / Vacunas de Partículas Similares a Virus / Anticuerpos Antibacterianos Límite: Animals Idioma: En Revista: Infect Immun Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Bordetella pertussis / Vacuna contra la Tos Ferina / Tos Ferina / Adhesinas Bacterianas / Vacunas de Partículas Similares a Virus / Anticuerpos Antibacterianos Límite: Animals Idioma: En Revista: Infect Immun Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos